Skip to content

US · LSTA · BIOTECHNOLOGY

Lisata Therapeutics, Inc. (LSTA) intrinsic value and stock valuation

$0.90as of 2026-11-21 · Mkt cap 10.12M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lisata Therapeutics, Inc. DCF and intrinsic value

InvestorsCraft values LSTA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LSTA’s statements →

Lisata Therapeutics, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Basking Ridge, NJ 07920 lisata.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$170K
20112025
Net income
-$-16.59M
20112025
Free cash flow
-$-15.98M
20112025
Total equity
$14.6M-14.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$170K$1M$0.00$0.00$0.00
Operating income-$-18.21M-$-22.41M-$-25.71M-$-57.6M-$-29.05M
Net income-$-16.59M-$-19.98M-$-20.84M-$-54.23M-$-27.47M
EPSd-$-1.91M-$-2.4M-$-2.58M-$-10.47M-$-7.44M
Operating cash flow-$-15.95M-$-19.36M-$-20.03M-$-21.17M-$-22.25M
Capital expenditure-$-30K$0.00$0.00-$-280K-$-60K
Free cash flow-$-15.98M-$-19.36M-$-20.03M-$-21.45M-$-22.3M
Total assets$17.7M$35M$54.7M$73M$97M
Total debt$0.00$140K$170K$480K$710K
Net debt-$-15.96M-$-16.07M-$-22.43M-$-31.67M-$-23.93M
Total equity$14.6M$29.3M$47.9M$66.3M$92M
Cash and short-term investments$16M$31.3M$50.5M$69.2M$95M
Income statement
20252024202320222021
Revenue$170K$1M$0.00$0.00$0.00
Cost of revenue$150K$0.00$0.00$0.00$0.00
Gross profit$20K$1M$0.00$0.00$0.00
Research and development expenses$7.95M$11.3M$12.7M$43.5M$17.6M
Selling, general and administrative expenses$10.4M$12.1M$13M$14.1M$11.5M
Other expenses-$-150K$0.00$0.00$0.00$0.00
Operating expenses$18.2M$23.4M$25.7M$57.6M$29.1M
Cost and expenses$18.4M$23.4M$25.7M$57.6M$29.1M
Interest income$810K$1.88M$2.72M$1.05M$150K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$150K$170K$190K$70K$60K
Ebitda-$-17.4M-$-20.61M-$-22.98M-$-56.63M-$-28.92M
Operating income-$-18.21M-$-22.41M-$-25.71M-$-57.6M-$-29.05M
Total other income/expenses, net$660K$1.63M$2.54M$900K$80K
Income before tax-$-17.55M-$-20.78M-$-23.17M-$-56.7M-$-28.97M
Income tax expense-$-960K-$-800K-$-2.33M-$-2.48M-$-1.51M
Net income-$-16.59M-$-19.98M-$-20.84M-$-54.23M-$-27.47M
Weighted average shares outstanding$8.69M$8.33M$8.07M$5.18M$3.69M
Weighted average diluted shares outstanding$8.69M$8.33M$8.07M$5.18M$3.69M
Balance sheet
20252024202320222021
Cash and short-term investments$16M$31.3M$50.5M$69.2M$95M
Net receivables$700K$900K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$17.7M$34.6M$53.9M$71.9M$96.2M
Property, plant and equipment, net$20K$70K$170K$300K$60K
Goodwill and intangible assets$0.00$190K$260K$330K$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$40K$420K$770K$1.16M$830K
Total assets$17.7M$35M$54.7M$73M$97M
Accounts payable$1.02M$1.28M$2.42M$2.65M$1.93M
Short-term debt$0.00$140K$170K$180K$230K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$3.07M$5.61M$6.59M$6.38M$4.52M
Long-term debt$0.00$0.00$0.00$300K$480K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$70K$70K$210K$330K$480K
Capital lease obligations$0.00$140K$170K$480K$710K
Total liabilities$3.14M$5.68M$6.8M$6.71M$5.01M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-564.65M-$-548.07M-$-528.08M-$-507.24M-$-453.02M
Accumulated other comprehensive income (loss)-$-40K-$-80K-$-40K-$-30K-$-70K
Total equity$14.6M$29.3M$47.9M$66.3M$92M
Total investments$0.00$15M$27.9M$37.1M$70.3M
Total debt$0.00$140K$170K$480K$710K
Net debt-$-15.96M-$-16.07M-$-22.43M-$-31.67M-$-23.93M
Cash flow statement
20252024202320222021
Net income-$-16.59M-$-19.98M-$-20.84M-$-54.23M-$-27.47M
Depreciation and amortization$150K$170K$190K$70K$60K
Stock-based compensation$1.23M$1.65M$2.04M$2.64M$2M
Change in working capital-$-1.29M-$-870K-$-460K-$-830K$650K
Accounts receivable$400K-$-900K$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable-$-2.57M-$-990K$90K-$-220K$1.25M
Net cash provided by operating activities-$-15.95M-$-19.36M-$-20.03M-$-21.17M-$-22.25M
Investments in property, plant and equipment-$-30K$0.00$0.00-$-280K-$-60K
Acquisitions, net$0.00-$-130K$0.00-$-3.32M$50K
Net cash used for investing activities$15.1M$13.2M$10.1M$28.9M-$-54.9M
Common stock issued$850K$70K$320K$40K$85.5M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$600K-$-210K$390K-$-220K$85.3M
Net change in cash-$-250K-$-6.38M-$-9.56M$7.51M$8.13M
Cash at end of period$16M$16.2M$22.6M$32.2M$24.7M
Operating cash flow-$-15.95M-$-19.36M-$-20.03M-$-21.17M-$-22.25M
Capital expenditure-$-30K$0.00$0.00-$-280K-$-60K
Free cash flow-$-15.98M-$-19.36M-$-20.03M-$-21.45M-$-22.3M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lisata Therapeutics, Inc.

        Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.

        CEO
        David J. Mazzo
        Employees
        21
        Beta
        0.80

        Explore

        Frequently asked questions

        What is the intrinsic value of Lisata Therapeutics, Inc. (LSTA)?

        InvestorsCraft does not currently publish an intrinsic value for LSTA. How the IC value is calculated.

        Is LSTA undervalued?

        InvestorsCraft does not publish an undervaluation signal for LSTA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.